A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer Harboring MET-alterations
| Title | A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer Harboring MET-alterations |
|---|---|
| Description | ESMO-ASIA publication_SCC244 in Met overexpression NSCLC |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA012402 |
| Release Date | 2024-10-10 |
| Submitter | shun Lu (shunlu_shchest@sina.com) |
| Organization | Shanghai Chest Hospital |
| Submission Date | 2022-10-10 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX002029-01 | ESMO-ASIA_SCC244 in Met overexpression NSCLC | 1 | Biomarker Data | 56.4 KB | zip | 0 | Controlled |
| OMIX002029-02 | Biomarker result | 1 | Biomarker Data | 57.3 KB | zip | 0 | Controlled |